NCT05470829 is a Phase 1 clinical trial of ZM-H1505R in Healthy Volunteers, sponsored by Shanghai Zhimeng Biopharma, Inc..

Who is sponsoring NCT05470829?

NCT05470829 is sponsored by Shanghai Zhimeng Biopharma, Inc..

What drugs are being tested in NCT05470829?

Interventions in NCT05470829: ZM-H1505R, ZM-H1505R Placebo.

What condition does NCT05470829 study?

NCT05470829 studies Healthy Volunteers, Hepatitis B, Chronic.

Is NCT05470829 still recruiting?

NCT05470829 is currently completed. Last updated 22 July 2022.

Last reviewed 2022-07-22 · How we verify

NCT05470829

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Multiple-dose Study in Chinese Subjects to Evaluate Safety,Tolerability,PK and PD of ZM-H1505R

Completed Phase 1 Last updated 22 July 2022

What this trial tests

Phase 1 trial testing ZM-H1505R in Healthy Volunteers in 42 participants. Completed in 17 November 2021.

Timeline

27 May 2021

Primary endpoint
17 November 2021

17 November 2021

Quick facts

Lead sponsor	Shanghai Zhimeng Biopharma, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	42
Start date	27 May 2021
Primary completion	17 November 2021
Estimated completion	17 November 2021
Sites	1 location across China

Drugs / interventions tested

ZM-H1505R — full drug profile →
ZM-H1505R Placebo

Conditions studied

Healthy Volunteers — all drugs for Healthy Volunteers →
Hepatitis B, Chronic — all drugs for Hepatitis B, Chronic →

Sponsor

Shanghai Zhimeng Biopharma, Inc. — full company profile →

Who can join

Adults 18 to 65, any sex, with Healthy Volunteers or Hepatitis B, Chronic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase Ib study included two parts in which Part I was to evaluate the safety and bridge for PK among healthy Chinese subjects and Part II were about study among Chinese chronic hepatitis B virus-infected patients. Study of Part II was carried out following the safety assessment and racial difference evaluation in Part I.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The premise of capsid assembly modulators towards eliminating HBV persistence.
Bassit L, Amblard F, Patel D, Biteau N, et al · · 2023 · cited 19× · PMID 37477111 · DOI 10.1080/17460441.2023.2239701
Safety, tolerability, pharmacokinetics, and antiviral activity of the novel core protein allosteric modulator ZM-H1505R (Canocapavir) in chronic hepatitis B patients: a randomized multiple-dose escalation trial.
Jia H, Mai J, Wu M, Chen H, et al · · 2023 · cited 15× · PMID 36927420 · DOI 10.1186/s12916-023-02814-w
Biology of the hepatitis B virus (HBV) core and capsid assembly modulators (CAMs) for chronic hepatitis B (CHB) cure.
McFadden WM, Sarafianos SG. · · 2023 · cited 9× · PMID 37655181 · DOI 10.35772/ghm.2023.01065

Verify or expand the search:

Other trials of ZM-H1505R

Trials testing the same drug.

NCT05484466 — A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patien · Phase 2 · unknown
NCT04220801 — A Study of Orally Administered ZM-H1505R to Evaluate Safety, Tolerability and Pharmacokinetics After Single and Multiple · Phase 1 · completed

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

NCT07504003 — Influence of Training Session Duration on Improvements in Physiological Resilience to Exercise · NA · recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07495813 — A Study to See How RO7763505 Works and How Safe it is When Given to Healthy People and People With Stable Heart Disease · Phase 1 · recruiting
NCT07499050 — A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity · Phase 1 · recruiting
NCT07342114 — A Dose-Escalation Study of RO7875913 in Healthy Participants · Phase 1 · recruiting

Other Shanghai Zhimeng Biopharma, Inc. trials

Trials by the same sponsor.

NCT05828745 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chroni · Phase 1 · completed
NCT06101316 — A Bridging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB06-036 in Healthy Subjects in China · Phase 1 · unknown
NCT05502549 — A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants in Australia · Phase 1 · completed
NCT05484466 — A Study to Evaluate the Efficacy and Safety of ZM-H1505R in Combination With ETV Compared With ETV Monotherapy in Patien · Phase 2 · unknown
NCT05499260 — A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05470829 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhimeng Biopharma, Inc.
Last refreshed: 22 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05470829.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing